AR048668A1 - Composiciones hipocolesterolemiantes y procedimiento para prepararlas - Google Patents
Composiciones hipocolesterolemiantes y procedimiento para prepararlasInfo
- Publication number
- AR048668A1 AR048668A1 ARP050100387A ARP050100387A AR048668A1 AR 048668 A1 AR048668 A1 AR 048668A1 AR P050100387 A ARP050100387 A AR P050100387A AR P050100387 A ARP050100387 A AR P050100387A AR 048668 A1 AR048668 A1 AR 048668A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- hypoocolesterolemiant
- prepare
- procedure
- pitavastatin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940008099 dimethicone Drugs 0.000 abstract 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 abstract 1
- 239000004205 dimethyl polysiloxane Substances 0.000 abstract 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960000672 rosuvastatin Drugs 0.000 abstract 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940083037 simethicone Drugs 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las composiciones de la presente comprenden una estatina seleccionada entre atorvastatina, cerivastatina, fluvastatina, lovastatina, pitavastatina, pravastatina, rosuvastatina, simvastatina, tanto en forma libre o como sales farmacéuticamente aceptables e hidratos correspondientes, más un agente antiflatulencia seleccionado entre simeticona y dimeticona. El procedimiento para preparar dichas composiciones hipocolesterolemiantes incluye el paso de compresion directa de sus componentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04002317A EP1563837A1 (en) | 2004-02-03 | 2004-02-03 | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048668A1 true AR048668A1 (es) | 2006-05-17 |
Family
ID=34684647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100387A AR048668A1 (es) | 2004-02-03 | 2005-02-02 | Composiciones hipocolesterolemiantes y procedimiento para prepararlas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080206328A1 (es) |
| EP (2) | EP1563837A1 (es) |
| JP (1) | JP2007520514A (es) |
| KR (1) | KR100815713B1 (es) |
| CN (1) | CN101094667A (es) |
| AR (1) | AR048668A1 (es) |
| AU (1) | AU2005210117A1 (es) |
| BR (1) | BRPI0507420A (es) |
| CA (1) | CA2556181A1 (es) |
| NO (1) | NO20063867L (es) |
| PA (1) | PA8622701A1 (es) |
| PE (1) | PE20050688A1 (es) |
| TW (1) | TW200529818A (es) |
| UY (1) | UY28729A1 (es) |
| WO (1) | WO2005074915A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1006879B (el) * | 2005-09-14 | 2010-07-13 | "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., | Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων |
| EP2018153B1 (en) | 2006-04-26 | 2012-04-11 | Rosemont Pharmaceuticals Ltd | Liquid oral compositions |
| US8835486B2 (en) * | 2006-05-12 | 2014-09-16 | Evangelos Karavas | Pharmaceutical formulation containing an HMG-COA reductase inhibitor and method for the preparation thereof |
| CN101229187B (zh) * | 2007-01-23 | 2011-09-28 | 德国柏林化学股份有限公司 | 西甲硅油乳剂及其制备方法 |
| HK1202445A1 (en) * | 2012-04-30 | 2015-10-02 | 霍夫曼-拉罗奇有限公司 | New formulation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444764A (en) * | 1979-08-06 | 1984-04-24 | The Dow Chemical Company | Phosphorus esters of alkylcycloalkyl-5-pyrimidinols and control of corn rootworm and western spotted cucumber beetle with them |
| DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| DE3322770C2 (de) * | 1983-06-24 | 1985-10-03 | Deutsche Gesellschaft für Wiederaufarbeitung von Kernbrennstoffen mbH, 3000 Hannover | Vorrichtung zur Handhabung und zum Schutz von Lagergebinden für radioaktive Stoffe |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| WO1995001780A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate combinations |
| IL154068A0 (en) * | 2000-07-27 | 2003-07-31 | Teva Pharma | Highly purified simvastatin compositions |
| EP1361867B1 (en) * | 2001-02-22 | 2007-03-21 | Jagotec AG | Fibrate-statin combinations with reduced fed-fasted effects |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| US6967218B2 (en) * | 2002-01-11 | 2005-11-22 | Biovail Laboratories, Inc. | Pravastatin pharmaceutical formulations and methods of their use |
| DE10209979A1 (de) * | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
| CA2379887C (en) * | 2002-04-09 | 2004-01-20 | Bernard Charles Sherman | Stable tablets comprising simvastatin |
| ZA200501508B (en) * | 2002-09-03 | 2006-10-25 | Biovail Lab Inc | Pharmaceuticals formulations and methods for modified release of statin drugs |
-
2004
- 2004-02-03 EP EP04002317A patent/EP1563837A1/en not_active Withdrawn
-
2005
- 2005-01-26 TW TW094102313A patent/TW200529818A/zh unknown
- 2005-01-27 PE PE2005000100A patent/PE20050688A1/es not_active Application Discontinuation
- 2005-01-27 UY UY28729A patent/UY28729A1/es unknown
- 2005-02-02 JP JP2006551796A patent/JP2007520514A/ja not_active Abandoned
- 2005-02-02 AR ARP050100387A patent/AR048668A1/es not_active Application Discontinuation
- 2005-02-02 US US10/588,377 patent/US20080206328A1/en not_active Abandoned
- 2005-02-02 BR BRPI0507420-7A patent/BRPI0507420A/pt not_active IP Right Cessation
- 2005-02-02 AU AU2005210117A patent/AU2005210117A1/en not_active Abandoned
- 2005-02-02 KR KR1020067015689A patent/KR100815713B1/ko not_active Expired - Fee Related
- 2005-02-02 CA CA002556181A patent/CA2556181A1/en not_active Abandoned
- 2005-02-02 EP EP05715243A patent/EP1713469A1/en not_active Withdrawn
- 2005-02-02 CN CNA2005800056595A patent/CN101094667A/zh active Pending
- 2005-02-02 WO PCT/EP2005/001038 patent/WO2005074915A1/en not_active Ceased
- 2005-02-03 PA PA20058622701A patent/PA8622701A1/es unknown
-
2006
- 2006-08-30 NO NO20063867A patent/NO20063867L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PA8622701A1 (es) | 2005-08-10 |
| WO2005074915A1 (en) | 2005-08-18 |
| BRPI0507420A (pt) | 2007-06-26 |
| NO20063867L (no) | 2006-10-26 |
| CA2556181A1 (en) | 2005-08-18 |
| US20080206328A1 (en) | 2008-08-28 |
| KR20060118579A (ko) | 2006-11-23 |
| TW200529818A (en) | 2005-09-16 |
| KR100815713B1 (ko) | 2008-03-20 |
| AU2005210117A1 (en) | 2005-08-18 |
| JP2007520514A (ja) | 2007-07-26 |
| EP1713469A1 (en) | 2006-10-25 |
| CN101094667A (zh) | 2007-12-26 |
| UY28729A1 (es) | 2005-03-31 |
| PE20050688A1 (es) | 2005-10-14 |
| EP1563837A1 (en) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8577901A1 (es) | Formulacion farmaceutica | |
| UY26883A1 (es) | Combinación terapéutica | |
| CR9425A (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| AR045203A1 (es) | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa | |
| EP1824442A4 (en) | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT | |
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| EA200970291A1 (ru) | Фармацевтическая композиция, содержащая розувастатин кальция | |
| BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
| GT200300053A (es) | Compuestos que modulan la actividad de ppar | |
| GT200300054A (es) | Compuestos que modulan la actividad de ppar | |
| DE602004020649D1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| HN2002000198A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
| PE20050148A1 (es) | Combinacion que comprende 2-metilpropanotioato de s-[2-({[1-(2-etilbutil)ciclohexil]carbonil}amino)fenilo] y un inhibidor de hmg coa reductasa | |
| ATE353214T1 (de) | Nitrooxyderivate von fluvastatin, pravastatin, cerivastatin, atorvastatin und rosuvastatin als cholesterinsenkende mittel mit verbesserter antiphlogistischer, antithrombotischer und thrombozytenaggregationshemmender wirkung | |
| EA200900073A1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| AR048668A1 (es) | Composiciones hipocolesterolemiantes y procedimiento para prepararlas | |
| DK1624869T3 (da) | Doseringsform indeholdende pantoprazol som aktiv bestanddel | |
| ATE444299T1 (de) | Neue boronatester | |
| AR065670A1 (es) | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas | |
| SE0302924D0 (sv) | Pharmaceutical composition having a cationic excipient | |
| BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
| GR20050100466A (el) | Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων | |
| BRPI0507859A (pt) | uso dos inibidores da colinesterase | |
| AR055091A1 (es) | Composiciones para reducir la incidencia de arritmia inducida por farmacos | |
| SE0301846D0 (sv) | Use of certain compounds in treatment of obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |